IP Library Granted Patent US 9,433,645
Granted Patent B2
US 9,433,645 · App. 14/394,402 · Granted Sep 6, 2016

Method and composition for preventing stem cell disruption and aggregation

Inventors: Jeong Chan Ra (Gyeonggi-do, KR); Sung Keun Kang (Seoul, KR); Il Seob Shin (Seoul, KR)
Assignees: Jeong Chan Ra; R BIO CO., LTD.
A61K35/28A61K31/616C12N5/0667C12N2500/30C12N2501/71C12N2501/999
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,433,645
App. No.
14/394,402
Granted
Sep 6, 2016
Kind
B2
Abstract

There is provided a method for preventing disruption and aggregation of stem cells. In addition, there is provided a stem cell composition for intravascular administration, in which stem cells are suspended in a solution containing aspirin. Further, there is provided a composition for preventing disruption or aggregation of stem cells, in which stem cells are suspended in a solution containing aspirin. According to the present invention, disruption and aggregation of cells may be prevented during transport or storage, such that the administered stem cells may stably reach the target tissue and exhibit the activity thereof in a more efficient manner, thereby remarkably increasing the effect of cell therapy using stem cells.

Claims (5)

1. A method for inhibiting disruption and aggregation of stem cells, the method comprising: suspending stem cells in a solution containing aspirin in an amount effective to inhibit said disruption and aggregation.

2. The method of claim 1 , wherein said solution containing aspirin further comprises normal saline, Hartman-D solution or phosphate buffered saline (PBS).

3. The method of claim 1 , wherein the aspirin is an amount of 0.0001 to 0.01 mg/ml.

4. The method of claim 1 , wherein said stem cells are adult stem cells.

5. The method of claim 4 , wherein said stem cells are adipose tissue-derived mesenchymal stem cells (AdMSCs).

Assignments (2)
CHANGE OF NAME Recorded Apr 1, 2016
From: K-STEMCELL CO., LTD.
To: R BIO CO., LTD
Reel/Frame 038581/0456 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2014
From: RA, JEONG CHAN; KANG, SUNG KEUN; SHIN, IL SEOB
To: K-STEMCELL CO., LTD.; RA, JEONG CHAN
Reel/Frame 034308/0220 →
Priority Claims (1)
KR 10-2012-0038828 · Apr 13, 2012 · national
Continuity (1)
Related Publication 20150118194A1 · Apr 30, 2015